Senior Correspondent, London
Ben's Feed
Dec 17, 2014
Dec 17, 2014

3D printing points way to smarter cancer treatment

LONDON (Reuters) – British scientists have developed a new use for 3D printing, putting it to work to create personalized replica models of cancerous parts of the body to allow doctors to target tumors more precisely.

The initiative is the latest example of medicine harnessing the rapidly emerging technology, which has already been used to manufacture some medical implants.

Dec 16, 2014
Dec 15, 2014
Dec 12, 2014
Dec 12, 2014

CERN particle smasher to turn back on at record power in March

LONDON (Reuters) – CERN’s Large Hadron Collider will be turned back on in March and a few weeks later will start smashing sub-atomic particles together again at nearly double its previous power, helping scientists hunt for clues about the universe.

The world’s biggest particle collider, located near Geneva, has been undergoing a two-year refit and work is now “in full swing” to start circulating proton beams again in March, with the first collisions due by May, the European Organization for Nuclear Research (CERN) said on Friday.

Dec 12, 2014
Dec 12, 2014
Dec 11, 2014

$300 million pledged to buy Ebola vaccines as NewLink shot hits snag

LONDON/GENEVA (Reuters) – GAVI, the global vaccines alliance, said on Thursday it was committing up to $300 million to buy Ebola vaccines, as one experimental shot hit a snag in a Swiss clinical trial after some subjects reported joint pains.

Scientists are racing to develop Ebola vaccines in record time but many questions remain unanswered, as evidenced by a decision to pause Swiss tests of the experimental vaccine from NewLink (NLNK.O: Quote, Profile, Research) and Merck (MRK.N: Quote, Profile, Research).

Dec 11, 2014

GAVI alliance commits up to $300 million to buy Ebola vaccines

LONDON (Reuters) – GAVI, the global vaccines alliance, said on Thursday it was committing up to $300 million to buy Ebola vaccines and was ready to begin procurement as soon as the World Health Organization recommends one for use.

As much as $90 million more could also be made available to help affected countries introduce the vaccines and to rebuild their health systems, it added.

    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben